Abstract:Malignant pleural effusion (MPE) occurs as a common complication of lung cancer with poor prognosis. It should be mainly attributed to pleura metastasis and lymphatic obstruction by cancer cells. Despite that intravenous immune-checkpoint inhibitor (ICIs) shows remarkable therapeutic capacity, the effect of thoracic injection of anti-PD-1 antibodies remains undefined. MPE xenografts mice model was established by intralumen injection of Lewis lung carcinoma (LLC) cells and randomly divided into three groups: high dose of anti-PD-1 monoclonal antibody (200ug), low dose of anti-PD-1 monoclonal antibody (50ug) and an equal volume of saline. Drugs were injected into the pleural cavity on Day 7 and Day 14. Computed tomography (CT) was performed 14 days after LLC injection. All mice were sacrificed on day 21 and the volume of pleural effusion, the number of pleural nodules were quantitatively recorded. Expression of PD-1, PD-L1, CD8+ and CD31 in tumor and normal pleural tissues were evaluated by western blot and immunohistochemical staining (IHC). Flow cytometry was performed on mice spleen after grinding. Weight and survival were recorded. The volume of pleural effusion, the number of pleural tumor foci and the proportion of CD8+ T cells in the spleen of mice were significantly reduced in both high and low dose of anti-PD-1 antibody treatment groups. Western Blot results showed that the expression of PD-1 in tumor and adjacent pleura was significantly inhibited after anti-PD-1antibody treatment. IHC results showed that CD8+ T cells in tumor area of mice in high dose anti-PD-1 monoclonal antibody group were significantly less than those in low dose group, and the expressions of PD-1 and PD-L1 were significantly increased. Anti-PD-1 monoclonal antibody treatment was associated with much longer survival (p=0.0098). Median survival in the anti-PD-1 antibody treated group was 39 days, versus 29 days in the control group. Intralumen delivery of anti-PD-1 antibody could significantly reduce MPE volume and improve survival by inhibiting the expression of PD-1, reducing the number of CD8+ T cells in the tumor region and spleen, and affecting angiogenesis.

Nuclear Factor-κB Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion

Establishment of a Malignant Pleural Effusion Mouse Model with Lewis Lung Carcinoma Cell Lines Expressing Enhanced Green Fluorescent Protein.

Effect of bevacizumab on angiogenesis and related cytokines in mice with malignant pleural effusion

Activated naïve B cells promote development of malignant pleural effusion by differential regulation of TH1 and TH17 response.

NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors

P1.03-24 Thoracic Injection of PD-1 Blocking Antibody Improves the Murine Model of Malignant Pleural Effusion

Diminished Expression of Transcription Factors Nuclear Factor Kappab and CCAAT/enhancer Binding Protein Underlies a Novel Tumor Evasion Mechanism Affecting Macrophages of Mammary Tumor-Bearing Mice.

Nf-Kappa B2 Mutation Targets Survival, Proliferation And Differentiation Pathways In The Pathogenesis Of Plasma Cell Tumors

Use of bioluminescent imaging to investigate the role of nuclear factor-κΒ in experimental non-small cell lung cancer metastasis

Use Of Bioluminescent Imaging To Investigate The Role Of Nuclear Factor-Kappa B In Experimental Non-Small Cell Lung Cancer Metastasis

Opposing Effects of Bortezomib-Induced Nuclear Factor-Κb Inhibition on Chemical Lung Carcinogenesis.

Nuclear Factor-κB Enhances ErbB2-Induced Mammary Tumorigenesis and Neoangiogenesis in Vivo

Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice

Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion

IL-10 promotes malignant pleural effusion in mice by regulating TH 1- and TH 17-cell differentiation and migration

Host Nuclear Factor-κB Activation Potentiates Lung Cancer Metastasis

Alterations In Nf-Kappa-B/Rel Family Proteins In Splenic T-Cells From Tumor-Bearing Mice And Reversal Following Therapy

Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion

IL‐10 promotes malignant pleural effusion in mice by regulating TH1‐ and TH17‐cell differentiation and migration

CSF1/CSF1R signaling mediates malignant pleural effusion formation

NEMO- and RelA-dependent NF-κB signaling promotes small cell lung cancer